Skip to main content
. 2022 Oct;11(10):3610–3619. doi: 10.21037/tcr-22-589

Figure 1.

Figure 1

Differential expression of MFN2 based on tumor status (cancer and paracancerous) (A), tumor status of matched cancer and paracancerous samples (B), clinical stage (C), and clinical stages I–III vs. stage IV (D). MFN2, mitofusin 2.